FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2178423748> ?p ?o ?g. }

• W2178423748 endingPage "2989" @default.
• W2178423748 startingPage "2985" @default.
• W2178423748 abstract "We report herein a series of substituted N-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amines as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase. Through structure–activity relationship studies, biochemical potency, pharmacokinetics, and kinase selectivity were optimized to afford BMS-645737 (13), a compound with good preclinical in vivo activity against human tumor xenograft models." @default.
• W2178423748 created "2016-06-24" @default.
• W2178423748 creator A5012391798 @default.
• W2178423748 creator A5012802503 @default.
• W2178423748 creator A5017784563 @default.
• W2178423748 creator A5023575873 @default.
• W2178423748 creator A5024867085 @default.
• W2178423748 creator A5032811880 @default.
• W2178423748 creator A5035465180 @default.
• W2178423748 creator A5037022305 @default.
• W2178423748 creator A5042216958 @default.
• W2178423748 creator A5042299848 @default.
• W2178423748 creator A5043623077 @default.
• W2178423748 creator A5045813781 @default.
• W2178423748 creator A5046176650 @default.
• W2178423748 creator A5048301603 @default.
• W2178423748 creator A5052378655 @default.
• W2178423748 creator A5054866179 @default.
• W2178423748 creator A5057427778 @default.
• W2178423748 creator A5058720590 @default.
• W2178423748 creator A5069156671 @default.
• W2178423748 creator A5084550335 @default.
• W2178423748 creator A5084736793 @default.
• W2178423748 creator A5087570789 @default.
• W2178423748 creator A5088484820 @default.
• W2178423748 creator A5089345330 @default.
• W2178423748 date "2008-05-01" @default.
• W2178423748 modified "2023-09-23" @default.
• W2178423748 title "Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor" @default.
• W2178423748 cites W1573363574 @default.
• W2178423748 cites W1971780920 @default.
• W2178423748 cites W1998241472 @default.
• W2178423748 cites W2024893931 @default.
• W2178423748 cites W2027514622 @default.
• W2178423748 cites W2037819581 @default.
• W2178423748 cites W2043421797 @default.
• W2178423748 cites W2047141305 @default.
• W2178423748 cites W2056895322 @default.
• W2178423748 cites W2058413420 @default.
• W2178423748 cites W2095140485 @default.
• W2178423748 cites W2097373408 @default.
• W2178423748 cites W2112911107 @default.
• W2178423748 cites W2149594845 @default.
• W2178423748 cites W2951162959 @default.
• W2178423748 doi "https://doi.org/10.1016/j.bmcl.2008.03.057" @default.
• W2178423748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18395443" @default.
• W2178423748 hasPublicationYear "2008" @default.
• W2178423748 type Work @default.
• W2178423748 sameAs 2178423748 @default.
• W2178423748 citedByCount "16" @default.
• W2178423748 countsByYear W21784237482012 @default.
• W2178423748 countsByYear W21784237482013 @default.
• W2178423748 countsByYear W21784237482015 @default.
• W2178423748 countsByYear W21784237482018 @default.
• W2178423748 countsByYear W21784237482021 @default.
• W2178423748 crossrefType "journal-article" @default.
• W2178423748 hasAuthorship W2178423748A5012391798 @default.
• W2178423748 hasAuthorship W2178423748A5012802503 @default.
• W2178423748 hasAuthorship W2178423748A5017784563 @default.
• W2178423748 hasAuthorship W2178423748A5023575873 @default.
• W2178423748 hasAuthorship W2178423748A5024867085 @default.
• W2178423748 hasAuthorship W2178423748A5032811880 @default.
• W2178423748 hasAuthorship W2178423748A5035465180 @default.
• W2178423748 hasAuthorship W2178423748A5037022305 @default.
• W2178423748 hasAuthorship W2178423748A5042216958 @default.
• W2178423748 hasAuthorship W2178423748A5042299848 @default.
• W2178423748 hasAuthorship W2178423748A5043623077 @default.
• W2178423748 hasAuthorship W2178423748A5045813781 @default.
• W2178423748 hasAuthorship W2178423748A5046176650 @default.
• W2178423748 hasAuthorship W2178423748A5048301603 @default.
• W2178423748 hasAuthorship W2178423748A5052378655 @default.
• W2178423748 hasAuthorship W2178423748A5054866179 @default.
• W2178423748 hasAuthorship W2178423748A5057427778 @default.
• W2178423748 hasAuthorship W2178423748A5058720590 @default.
• W2178423748 hasAuthorship W2178423748A5069156671 @default.
• W2178423748 hasAuthorship W2178423748A5084550335 @default.
• W2178423748 hasAuthorship W2178423748A5084736793 @default.
• W2178423748 hasAuthorship W2178423748A5087570789 @default.
• W2178423748 hasAuthorship W2178423748A5088484820 @default.
• W2178423748 hasAuthorship W2178423748A5089345330 @default.
• W2178423748 hasConcept C104264131 @default.
• W2178423748 hasConcept C112705442 @default.
• W2178423748 hasConcept C114373084 @default.
• W2178423748 hasConcept C118792377 @default.
• W2178423748 hasConcept C121608353 @default.
• W2178423748 hasConcept C126322002 @default.
• W2178423748 hasConcept C150903083 @default.
• W2178423748 hasConcept C155647269 @default.
• W2178423748 hasConcept C161790260 @default.
• W2178423748 hasConcept C170493617 @default.
• W2178423748 hasConcept C185592680 @default.
• W2178423748 hasConcept C193042331 @default.
• W2178423748 hasConcept C202751555 @default.
• W2178423748 hasConcept C207001950 @default.
• W2178423748 hasConcept C24961977 @default.
• W2178423748 hasConcept C2778820342 @default.
• W2178423748 hasConcept C42362537 @default.
• W2178423748 hasConcept C55493867 @default.

• next